

Current status of Universal Screening for Lynch syndrome

Heather Hampel, MS, CGC



The James

Ohio State is a Comprehensive Cancer Center designated by the National Cancer Institute

**NCI
CCC**

A Comprehensive Cancer Center Designated by the National Cancer Institute

Collaboration with City of Hope

- In press in JCO as of 9/9/11
- 39 NCI-designated Comprehensive Cancer Centers
- 50 randomly selected ACS-accredited Community Hospital Comprehensive Cancer Programs (COMPs)
- 50 randomly selected Community Hospital Cancer Programs (CHCPs)
- Overall response rate was 50%
 - 63% for NCI-CCCs
 - 50% for COMPs
 - 40% for CHCPs

Reflex IHC/MSI

- Reflex IHC/MSI is being conducted at
 - 71% of NCI-CCCs
 - 36% of COMPs
 - 15% of CHCPs
- 16% of those not doing reflex testing were planning to do so
- Test utilized
 - 48% use IHC
 - 14% use MSI
 - 38% use both

Champion of Reflex testing

- Pathologists (35%)
- Genetic health care providers (17%)
- Other providers (38%)
- No one person (8%)

Who is being tested

- 38% testing ALL new cases of CRC
- 27% testing CRC dx < 50
- 14% testing CRC dx < 60
- 21% using other selection processes

Pre-operative practices

- 79% do not routinely use any additional pre-operative practices (eg. Brochures)
- 14% offered option to opt-out of reflex testing
- 3.5% offered pre-operative packet that included information on reflex testing for LS
- 3.5% did not specify the written materials used
- None of the responding programs required written informed consent

Reflex result recipients

- 27.6% go to the surgeon alone
- 55.2% go to the surgeon & another health care provider
- 6.9% go to a genetic health care provider alone
- 6.9% go to a non-surgeon & a non-genetic health care provider
- 3.4% go to no one

Referrals for Genetic Services

- All the COMPs and CHCPs expected the referrals to genetics to be initiated by the person receiving the reflex test results
- NCI-CCCs showed greater diversity
 - 65% initiated by the result receiver
 - 18% initiated by an automatic electronic mechanism
 - 17% initiated by a specialist

Monitoring Genetics Referral Process

- A tracking mechanism has been implemented by
 - 58.8% of NCI-CCCs
 - 44.4% of COMPs
 - 66.7% of CHCPs
- Among those tracking the process, problems with patient follow-up to genetics were reported by
 - 53% of NCI-CCCs
 - 33% of COMPs
 - 67% of CHCPs

Comments

- “It’s very messy. This has been a battle...”
- Pathologists think they can tell by their review if it needs MSI/IHC”
- “Genetics has been pushing for universal screening – with no luck.”
- “Our pathologist/molecular diagnostics do not feel they will get reimbursed for all MSI studies, which is why we have limited it to under 50”
- “...I am frequently asked, ‘What is everyone else doing?’”